Global Blood Therapeutics Inc (NASDAQ:GBT) Expected to Post Quarterly Sales of $550,000.00

Brokerages expect Global Blood Therapeutics Inc (NASDAQ:GBT) to report $550,000.00 in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Global Blood Therapeutics’ earnings, with the lowest sales estimate coming in at $30,000.00 and the highest estimate coming in at $1.09 million. The business is expected to report its next earnings report on Wednesday, February 26th.

On average, analysts expect that Global Blood Therapeutics will report full-year sales of $550,000.00 for the current year, with estimates ranging from $30,000.00 to $1.09 million. For the next fiscal year, analysts forecast that the firm will report sales of $45.39 million, with estimates ranging from $21.10 million to $68.99 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.04). During the same period in the previous year, the company posted ($0.83) EPS.

GBT has been the subject of a number of recent analyst reports. Cowen set a $83.00 price target on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 9th. JPMorgan Chase & Co. increased their price objective on shares of Global Blood Therapeutics from $58.00 to $79.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Oppenheimer reissued a “buy” rating and issued a $100.00 price objective on shares of Global Blood Therapeutics in a research note on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and set a $150.00 price target on shares of Global Blood Therapeutics in a research note on Wednesday, October 9th. Finally, William Blair reiterated a “buy” rating on shares of Global Blood Therapeutics in a research report on Wednesday, December 18th. Six research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $95.19.

In related news, insider Tricia Borga Suvari sold 3,327 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $48.45, for a total transaction of $161,193.15. Following the completion of the transaction, the insider now owns 12,386 shares of the company’s stock, valued at $600,101.70. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Joshua Lehrer-Graiwer sold 11,593 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $67.19, for a total transaction of $778,933.67. Following the completion of the transaction, the insider now directly owns 312 shares of the company’s stock, valued at approximately $20,963.28. The disclosure for this sale can be found here. Insiders sold a total of 97,490 shares of company stock valued at $7,020,482 in the last three months. 4.30% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in GBT. Truvestments Capital LLC grew its position in Global Blood Therapeutics by 48.0% during the 3rd quarter. Truvestments Capital LLC now owns 925 shares of the company’s stock valued at $45,000 after purchasing an additional 300 shares during the last quarter. Lindbrook Capital LLC grew its holdings in Global Blood Therapeutics by 133.3% during the 3rd quarter. Lindbrook Capital LLC now owns 700 shares of the company’s stock valued at $34,000 after buying an additional 400 shares in the last quarter. Quest Capital Management Inc. ADV purchased a new stake in Global Blood Therapeutics during the 3rd quarter valued at approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Global Blood Therapeutics by 16.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,814 shares of the company’s stock valued at $185,000 after buying an additional 549 shares in the last quarter. Finally, Prudential Financial Inc. grew its holdings in Global Blood Therapeutics by 11.1% during the 2nd quarter. Prudential Financial Inc. now owns 5,623 shares of the company’s stock valued at $296,000 after buying an additional 560 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

Shares of GBT stock traded down $0.47 on Monday, reaching $80.36. The stock had a trading volume of 394,043 shares, compared to its average volume of 816,753. Global Blood Therapeutics has a 12 month low of $43.69 and a 12 month high of $87.54. The firm has a market capitalization of $4.87 billion, a price-to-earnings ratio of -20.71 and a beta of 1.75. The firm’s 50-day moving average is $79.78 and its two-hundred day moving average is $58.85. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.04.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Read More: Limitations of the P/E Growth ratio

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.